
Voxelotor tablets
Form: Tablet
Strength: 500 mg
Reference Brands: Oxbryta(US)
Category: Blood Disorder
Voxelotor, marketed as Oxbryta, is approved in the US by the FDA for treating sickle cell disease. In the EU, regulatory approval is pending or under review. Approval requires a comprehensive dossier including clinical trial data, safety, efficacy, pharmacovigilance, and manufacturing details. In the US, submission involves detailed clinical study review, while the EU follows EMA guidelines for authorization. For guidance on dossier preparation, regulatory pathways, and successful market entry strategies, visit PharmaTradz. Ensuring compliance with regional regulations is essential for the safe, approved, and effective use of voxelotor worldwide, supporting patients with sickle cell disease.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Anti-Inhibitor Coagulant Complex (AICC) Lyophilized Powder
Strength: 500 units, 1000 units, and 2500 units
Form: Lyophilized Powder (Reconstituted for IV infusion)
Reference Brands: FEIBA(US)
View Details Get EnquiryProthrombin Complex Concentrate (PCC) injection
Strength: 250 IU to 300 IU
Form: Injection
Reference Brands: Kcentra (4-factor PCC), Bebulin VH (3-factor PCC)(US)
View Details Get EnquiryMesna Injection
Strength: 100 mg/mL
Form: Injection
Reference Brands: Mesnex(US)
View Details Get EnquiryLeucovorin tablets/Capsule
Strength: 15 mg, 50 mg
Form: Tablet/Capsules
Reference Brands: Folvite(US & EU)
View Details Get Enquiry